PROSPective Evaluation of Outcome After CatheTer Ablation in Atrial Fibrillation

Last updated: February 5, 2025
Sponsor: University Hospital, Lille
Overall Status: Active - Recruiting

Phase

N/A

Condition

Arrhythmia

Chest Pain

Dysrhythmia

Treatment

atrial fibrillation catheter ablation

Clinical Study ID

NCT05009797
2018_83
2020-A02171-38
  • Ages > 18
  • All Genders

Study Summary

Atrial fibrillation ablation is the most common intervention performed worldwide. Up to 20 to 45% of patients show recurrence of AF within 12 month after catheter ablation, however its determinant are incompletely understood.

The aim of the PROSPECT-AF study is to assess the predictors of AF recurrence within the 3 years following ablation using clinical variables and innovative biomarkers in a prospective cohort of 750 patients undergoing atrial fibrillation catheter ablation.

The secondary aims are to assess the incidence of major adverse cardiovascular outcomes (MACE) and the incidence of major bleeding within the 3 years Wolfing catheter ablation.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patient undergoing atrial fibrillation catheter ablation

  • Able to give their consent

Exclusion

Exclusion Criteria:

  • Childs

  • Patient under guardianship

  • Patients unable to give their consent

  • Pregnancy

Study Design

Total Participants: 750
Treatment Group(s): 1
Primary Treatment: atrial fibrillation catheter ablation
Phase:
Study Start date:
February 16, 2023
Estimated Completion Date:
February 28, 2031

Connect with a study center

  • Institut Coeur-Poumon, CHU

    Lille,
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.